This ExpertREACT article was originally published on 15 December 2008. Financial results and market positions described reflect the state of knowledge at that date.
2008: another year of industry growth
According to VacZine Analytics' calculations, the top five vaccine companies sold nearly $13bn in vaccines to the end of Q3 2008 - already exceeding the full year total for 2006. If Q4 2008 performance matched the Q3/Q4 ratio seen in 2007, full year 2008 sales were predicted at approximately $16.4bn, slightly above 2007. The top-selling vaccine products of 2008 included Merck & Co's HPV vaccine Gardasil - which had generated over $1bn in US sales to Q3 2008 with strong EU growth - and Wyeth's pneumococcal vaccine Prevnar (PCV-7) at $2.7bn worldwide. Merck stated it had sold an estimated 30 million doses of Gardasil globally.
While Gardasil remained the industry's flagship product, its US growth trajectory was clearly flattening in 2008. EU sales were growing rapidly - potentially reaching 70% of the US total by year-end - as the company won government tenders in France, Germany and Belgium. GSK's Cervarix was building competitive pressure through national immunisation programme wins, most notably the UK's national HPV programme. The competitive dynamics between Gardasil and Cervarix - differing in antigen content, adjuvant system and target indications - were expected to define HPV vaccine market evolution in the near term, with Cervarix awaiting a critical US FDA decision.
New launches to drive 2009/10 growth
VacZine Analytics identified the forthcoming launches of next-generation pneumococcal (PCV-13) and new meningococcal ACWY vaccines (Menveo, expanded Menactra) as the primary growth catalysts for 2009-2010. A wave of consolidation had also accelerated - Novartis/Chiron (2006), Sanofi/Acambis (2008), AstraZeneca/Medimmune (2007) - suggesting the major players were building diversified vaccine pipelines to sustain growth beyond current blockbuster lifecycles. The article concluded that the vaccine industry entered 2009 from a position of strength, but that execution of new product launches and successful pipeline progression were essential to maintaining momentum.